• Explore /
  • Poster
  • / Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.

Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcinoma (CCA) before and during adjuvant chemotherapy (ACT): Sub-analysis of the randomized phase 2 STAMP trial.

Abstract Poster

Authors

null

Changhoon Yoo

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Changhoon Yoo , George Laliotis , Hyehyun Jeong , Jae Ho Jeong , Kyu-Pyo Kim , Seonmin Lee , Baek-Yeol Ryoo , Shruti Sharma , Punashi Dutta , Meenakshi Malhotra , Adham A Jurdi , Minetta Liu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Hepatobiliary Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT03079427

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4123)

DOI

10.1200/JCO.2023.41.16_suppl.4123

Abstract #

4123

Poster Bd #

444

Abstract Disclosures

Similar Posters

First Author: Changhoon Yoo

First Author: Van K. Morris II

First Author: Van K. Morris II

First Author: Van K. Morris II